RxDoctor Payments Data

Sumeesh Dhawan, MD

Internal Medicine · Arlington, TXNPI 1255428827

Payments from drug & device makers

$439in general payments, 2019–2025

Across 11 payments — averaging $39.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$209
  • Pfizer$66
  • Astellas Pharma US Inc$60
  • Avanir Pharmaceuticals, Inc.$57
  • Abbott$21
  • Angiodynamics, Inc.$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$37986%
  • Education$6014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$439 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$256,988
Medicare patients
672
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban406$157,366
TrulicityDulaglutide58$65,024
JardianceEmpagliflozin66$58,907
Soliqua 100-33Insulin Glargine/Lixisenatide42$48,939
OzempicSemaglutide35$46,895
FarxigaDapagliflozin Propanediol74$43,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$41,074
EntrestoSacubitril/Valsartan66$35,374
XareltoRivaroxaban69$30,600
JanuviaSitagliptin Phosphate50$27,418
GemtesaVibegron90$21,557
MyrbetriqMirabegron65$20,902
JanumetSitagliptin Phos/Metformin Hcl12$16,681
Repatha SyringeEvolocumab21$12,751
Repatha SureclickEvolocumab11$10,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$157,366406 claims
Novo NordiskOzempic$209$46,89535 claims
NovartisEntresto$12$35,37466 claims
Astellas Pharma US IncMyrbetriq$60$20,90265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →